Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Sarcoma 4Gynecologic 3Genitourinary 3Other hematologic neoplasm 2Dermatologic 2CNS 2Breast 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1NET 1Gastrointestinal 1Endocrine 1Classical hematology 1

Conditions

Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Sarcoma 2Pheochromocytoma 2Ovarian Neoplasms 2Neurofibrosarcoma 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Liposarcoma 2Leiomyosarcoma 2Kidney Neoplasms 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Head and Neck Neoplasms 2Fibrosarcoma 2Endometrial Neoplasms 2Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Filgrastim × Endocrine × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡